Press Releases
[Oct 2009] PolyTherics Announces New Senior Management Appointments: Strengthening of team prepares company for future product development strategy
PolyTherics Limited, the biopharmaceuticals company dedicated to precision engineering of proteins to improve their pharmacokinetic properties, today announced two key appointments to its senior management team. The announcement comes as PolyTherics is poised to expand its capabilities for developing PEGylated biopharmaceuticals for therapeutic application.
[Sep 2009] PolyTherics and Minapharm Pharmaceuticals sign Collaboration Agreement to create enhanced biopharmaceuticals
PolyTherics Limited, the biopharmaceuticals company dedicated to precision engineering of proteins to improve their pharmacokinetic properties, today announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals the leading Egyptian pharmaceutical company. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to Minapharm.
[Jul 2009] PolyTherics Receives Second Patent Allowance in Record Time
PolyTherics Limited, the biopharmaceuticals company dedicated to precision engineering of biologics to improve their pharmacokinetic properties, is delighted to announce that a second patent has been allowed covering the targeted PEGylation of proteins. Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This exciting news comes just two weeks after the allowance of the first patent within Europe.
[Jun 2009] PolyTherics TheraPEG™ Patent Allowed in Europe
PolyTherics Limited, the biopharmaceuticals company dedicated to precision engineering of biologics to improve their pharmacokinetic properties, is delighted to announce that its first patent covering the targeted PEGylation of proteins has been allowed in Europe. The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins.
[May 2009] PolyTherics and Celtic Pharma enter Product Licence Agreement for novel optimised biopharmaceuticals
PolyTherics today announced the extension of its relationship with Celtic Pharma Development Services Bermuda Ltd (“Celtic Pharma”), the global private equity investment fund focused on the development of therapeutic products in the biopharma industry. An initial collaboration agreement was entered into just over twelve months ago, aimed at generating modified biologics with improved half-life and predictable bioactivity. PolyTherics has now granted Celtic Pharma an exclusive licence to develop and commercialise the first novel biotherapeutic discovered in this collaboration.
[Apr 2009] PolyTherics to present recent developments in improving antibody fragments for therapeutic use at PEGS Protein Engineering Summit, Boston
PolyTherics, the biopharmaceuticals company dedicated to precision engineering of protein half-life is pleased to announce its attendance at the 5th Annual PEGS conference in Boston, USA. Dr Ji-won Choi, Head of Biology will present data tomorrow showing that novel recombinant antibody fragments can be selectively modified by PEGylation without compromising their bioactivity.
[Apr 2009] Biotech chief bemoans lack of start-up cash
Keith Powell believes UK start-ups suffer unduly from the limited venture capital funding available for early-stage businesses. “It is survival of the fittest in Europe,” he said. “In the US, there is more venture capital available. Companies can focus on developing products rather than staying in business.”
[Jan 2009] PolyTherics comes together for Annual Christmas Dinner
PolyTherics members take off their white lab coats and dress up in celebration of another successful year on the night of their Annual Christmas Dinner.
